Linezolid-d8
- CAS No.
- 1032182-14-1
- Chemical Name:
- Linezolid-d8
- Synonyms
- Linezolid-d8;Acetamide, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl-2,2,3,3,5,5,6,6-d8)phenyl]-2-oxo-5-oxazolidinyl]methyl]-
- CBNumber:
- CB82610997
- Molecular Formula:
- C16H12D8FN3O4
- Molecular Weight:
- 345.4
- MDL Number:
- MOL File:
- 1032182-14-1.mol
- MSDS File:
- SDS
SAFETY
Risk and Safety Statements
| Symbol(GHS) |    GHS02,GHS06,GHS08 |
|---|---|
| Signal word | Danger |
| Hazard statements | H225-H301+H311+H331-H370 |
| Precautionary statements | P210-P233-P280-P301+P310-P303+P361+P353-P304+P340+P311 |
| target organs | Eyes,Central nervous system |
| WGK Germany | WGK 2 |
| Storage Class | 3 - Flammable liquids |
| Hazard Classifications | Acute Tox. 3 Dermal Acute Tox. 3 Inhalation Acute Tox. 3 Oral Flam. Liq. 2 STOT SE 1 |
Linezolid-d8 Chemical Properties, Uses, Production
Uses
PNU-100766-d8 is deuterated labeled Linezolid (HY-10394). Linezolid (PNU-100766) is the first member of the class of oxazolidinone synthetic antibiotic. Linezolid acts by inhibiting the initiation of bacterial protein synthesis. Linezolid is used for the treatment of serious infections caused by Gram-positive bacteria that are resistant to several other antibiotics[1][2][3].
References
[1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. DOI:10.1177/1060028018797110
[2] Clemett D, Markham A. Linezolid. Drugs. 2000 Apr;59(4):815-27; discussion 828. DOI:10.2165/00003495-200059040-00007
[3] Chiappini E, Conti C, Galli L et al. Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Clin Ther. 2010 Jan;32(1):66-88. DOI:10.1016/j.clinthera.2010.01.019
[4] Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs. 2001;61(4):525-51. DOI:10.2165/00003495-200161040-00008
[5] He MZ, Jiang YW, Cai C.
Mechanisms and epidemiology of linezolid resistance in staphylococci.Zhonghua Jie He He Hu Xi Za Zhi. 2012 May;35(5):360-2. PMID:22883997
[6] Karau MJ, Tilahun AY, Schmidt SM, Clark CR, Patel R, Rajagopalan G.
Linezolid is Superior to Vancomycin in Experimental Pneumonia Caused by Superantigen-Producing Staphylococcus aureus in HLA class II Transgenic Mice.
Antimicrob Agents Chemother. 2012 Jul 30. DOI:10.1128/AAC.01080-12
Linezolid-d8 Preparation Products And Raw materials
Raw materials
Preparation Products
Linezolid-d8 Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Quality Control Solutions Ltd. | 0755-66853366 13670046396 | orders@qcsrm.com | China | 18188 | 56 |
| Pushan Industry (Shaanxi) Co., Ltd. | 029-81310890 18165209495 | 2929288192@qq.com | China | 9949 | 58 |
| Shanghai YuZn Pharm. Technology Co.,Ltd. | 15921286451; 15921286451 | 2010681527@qq.com | China | 4918 | 58 |
| Shandong Dayou Pharmaceutical Research and Development Co., Ltd. | hanfangpharma@126.com 15165037910 | hanfangpharma@126.com | China | 25800 | 58 |
| Changzhou Xianglong Pharmaceutical Technology Co., Ltd., | 18915873328 18915873328 | sales@xianglongpharm.com | China | 11049 | 58 |
